Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04YEW
|
|||
| Former ID |
DIB005258
|
|||
| Drug Name |
Tarafenacin
|
|||
| Synonyms |
SVT-40776; Muscarinic M3 receptor antagonist (overactive bladder), SALVAT
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Overactive bladder [ICD-11: GC50.0; ICD-10: N32.8] | Phase 2 | [1] | |
| Company |
Laboratorios SALVAT SA
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H20F4N2O2
|
|||
| Canonical SMILES |
C1CN2CCC1C(C2)OC(=O)N(CC3=CC(=C(C(=C3)F)F)F)C4=CC(=CC=C4)F
|
|||
| InChI |
1S/C21H20F4N2O2/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26/h1-3,8-10,14,19H,4-7,11-12H2/t19-/m0/s1
|
|||
| InChIKey |
UXZDMXYRRQJIBJ-IBGZPJMESA-N
|
|||
| CAS Number |
CAS 385367-47-5
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01458197) A Phase 2 Study to Compare the Efficacy and Tolerability of Tarafenacin 0.2 mg and Tarafenacin 0.4 mg to Placebo in Patients Suffering From Overactive Bladder.. U.S. National Institutes of Health. | |||
| REF 2 | In vivo and in vitro pharmacological characterization of SVT-40776, a novel M3 muscarinic receptor antagonist, for the treatment of overactive bladder. Br J Pharmacol. 2009 Mar;156(5):807-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.